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Background
Data to guide the order in which ipilimumab and
vemurafenib are used in patients with advanced mela-
noma are limited. Here are reported outcomes from
patients treated in the ipilimumab EAP who received
both drugs.
Methods
Patients with pretreated, BRAFV600 mutation-positive
advanced melanoma who had received BRAF inhibitor
before or after ipilimumab were eligible for analysis.
Results
93 patients were eligible: 48 patients received a BRAF
inhibitor after ipilimumab and 45 patients ipilimumab
after a BRAF inhibitor. Median overall survival (OS) was
14.5 and 9.9 months for the two groups, respectively
(P=0.04). Among patients who received a BRAF inhibi-
tor first, 18 (40%) had rapid disease progression and
were unable to complete ipilimumab treatment as for
protocol (rapid progressors). For this group median OS
from the cessation of treatment with a BRAF inhibitor
was 1.2 months. 27 patients had slower disease progres-
sion and were able to complete all four doses of ipilimu-
mab (slow progressors); median OS was significantly
longer (12.7 months; P<0.0001).Younger age and the
presence of brain metastasis were significantly associated
with a poorer outcome (P=0.02).
Conclusions
This EAP data suggests that pretreated, BRAF-mutated
patients who have rapid disease progression upon failing
treatment with a BRAF inhibitor die in one month, so
they may benefit from receiving ipilimumab as the first
part of their sequential regimen, otherwise clinical bene-
fit may be limited due to them not being able to receive
the full induction treatment.
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